×
About 993 results

ALLMedicine™ Angioimmunoblastic T-cell Lymphoma Center

Research & Reviews  317 results

Transplantation After Complete Response In Patients With T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05444712

Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
https://clinicaltrials.gov/ct2/show/NCT04251065

Aug 2nd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
https://clinicaltrials.gov/ct2/show/NCT04858256

Aug 1st, 2022 - Patients will receive single-agent treatment with pacritinib 200mg orally twice daily until any condition for treatment discontinuation has been met. Patients will be enrolled into one of four cohorts: Peripheral T-Cell Lymphoma, not otherwise spe...

Diagnostic utility of the aberrant immunohistochemical expression of CD3 molecules for ...
https://doi.org/10.1016/j.anndiagpath.2022.152013
Annals of Diagnostic Pathology; Satoh T, Kayano H et. al.

Jul 30th, 2022 - The histological diagnosis of peripheral T-cell lymphomas (PTCLs) is often challenging. Flow cytometry (FCM) sometimes shows the loss of pan-T-cell markers for PTCLs, suggesting the neoplastic nature of these cells. Immunohistochemically, the tota...

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02520791

Jul 19th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

see more →

Guidelines  1 results

T-Cell Lymphomas, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology.
https://doi.org/10.6004/jnccn.2022.0015
Journal of the National Comprehensive Cancer Network : JN... Horwitz SM, Ansell S et. al.

Mar 12th, 2022 - Peripheral T-cell lymphomas (PTCLs) are a heterogeneous group of lymphoproliferative disorders arising from mature T cells, accounting for about 10% of non-Hodgkin lymphomas. PTCL-not otherwise specified is the most common subtype, followed by ang...

see more →

Drugs  1 results see all →

Clinicaltrials.gov  28 results

Transplantation After Complete Response In Patients With T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT05444712

Aug 4th, 2022 - Peripheral T-cell lymphoma (PTCL) encompasses a broad range of post-thymic (i.e., mature) sub-entities as defined by the 2017 WHO classification. The most common entities are angioimmunoblastic T-cell lymphoma (AITL) and other Tfh-phenotype PTCL o...

Daratumumab Plus Gemcitabine, Dexamethasone, Cisplatin in pt R/R CD38+ PTCL-NOS, AITL and TFH
https://clinicaltrials.gov/ct2/show/NCT04251065

Aug 2nd, 2022 - This is an open-label, multicenter, single arm, single-stage phase II trial. After the patient signs the written informed consent the patient will enter the screening phase planning baseline assessments and a concomitant upfront confirmation of di...

Pacritinib in Relapsed/Refractory T-cell Lymphoproliferative Neoplasms
https://clinicaltrials.gov/ct2/show/NCT04858256

Aug 1st, 2022 - Patients will receive single-agent treatment with pacritinib 200mg orally twice daily until any condition for treatment discontinuation has been met. Patients will be enrolled into one of four cohorts: Peripheral T-Cell Lymphoma, not otherwise spe...

Anti-ICOS Monoclonal Antibody MEDI-570 in Treating Patients With Relapsed or Refractory Peripheral T-cell Lymphoma Follicular Variant or Angioimmunoblastic T-cell Lymphoma
https://clinicaltrials.gov/ct2/show/NCT02520791

Jul 19th, 2022 - PRIMARY OBJECTIVE: I. To determine the safety, maximum tolerated dose and recommended phase II dose (RP2D) of anti-ICOS monoclonal antibody MEDI-570 (MEDI-570) in patients with refractory/relapsed peripheral T-cell lymphoma-not otherwise specified...

T Cells Expressing a Fully-Human Anti-CD30 Chimeric Antigen Receptor for Treating CD30-Expressing Lymphomas
https://clinicaltrials.gov/ct2/show/NCT03049449

May 25th, 2022 - Background: Improved treatments for a variety of treatment-resistant, TNFRSF8 (CD30)-expressing malignancies including Hodgkin lymphoma, anaplastic large cell lymphoma, and other CD30- expressing lymphomas are needed. T cells can be genetically mo...

see more →

News  50 results

Angioimmunoblastic T-cell Lymphoma Mimicking DRESS Syndrome
https://www.mdedge.com/dermatology/article/253247/urticaria/angioimmunoblastic-t-cell-lymphoma-mimicking-dress-syndrome
Morgan Keefe, DO, MPH, Talayesa Buntinx-Krieg, MD et. al.

Mar 29th, 2022 - Angioimmunoblastic T-cell lymphoma (AITL) is a rare and aggressive lymphoma arising from follicular T-helper cells that predominantly affects older adults and carries a 5-year overall survival rate of 32%. 1 Notably, as many as 50% of AITL patients.

PTCL Community Treatment and Future Advancements
https://www.onclive.com/view/ptcl-community-treatment-and-future-advancements

Apr 2nd, 2021 - Transcript: Neha Mehta-Shah, MD: Dr Chadi Nabhan at ASH [the American Society of Hematology Annual Meeting & Exposition] this year presented a retrospective review of about 200 patients who have peripheral T-cell lymphoma across a number of su...

Peripheral T-Cell Lymphoma Classifications and CD30 Testing
https://www.onclive.com/view/peripheral-t-cell-lymphoma-classifications-and-cd30-testing

Apr 2nd, 2021 - Transcript: Neha Mehta-Shah, MD: Peripheral T-cell lymphomas are a relatively uncommon subset of non-Hodgkin lymphomas. They make up about 10% of all non-Hodgkin lymphomas. There are about 7000 cases per year. About half of those are the syste...

Flow cytometry identifies rare combination of lymphoma and MDS
https://www.mdedge.com/hematology-oncology/article/234164/myelodysplastic-syndrome/flow-cytometry-identifies-rare

Jan 5th, 2021 - Key clinical point: Researchers used flow cytometry and genomic assessment to identify a shared DNMT3A mutation in a rare case of angioimmunoblastic T-cell lymphoma and myelodysplastic syndrome. Major finding: DNMT3A N612Rfs*36 was identified as t.

Anti-ICOS Antibody MEDI-570 Elicits Durable Responses in Relapsed/Refractory T-cell Lymphomas
https://www.onclive.com/view/anti-icos-antibody-medi-570-elicits-durable-responses-in-relapsed-refractory-t-cell-lymphomas

Dec 20th, 2020 - The anti-inducible T-cell co-stimulator (ICOS) monoclonal antibody MEDI-570 showed clinical activity with durable responses, as well as acceptable safety and tolerability in patients with relapsed/refractory angioimmunoblastic T-cell lymphoma (AIT...

see more →